VRTX · 8-K · 20260707PR296710

Guidance / Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-07-07 · Importance 67 · Surprise 76 · In source text

Vertex stated that its 2026 guidance will be updated when the anticipated Crinetics transaction closes in the third quarter of 2026. Because of the expected closing timing, management anticipates only a modest effect on 2026 revenue and non-GAAP operating expenses. Over the longer term, Vertex expects the transaction to accelerate revenue growth, support sustained double-digit revenue growth, and become accretive to non-GAAP operating income in 2029.

Key facts

• Vertex expects the acquisition to accelerate Vertex’s revenue growth and enhance long-term earnings profile. source
• Vertex expects the Transaction to become accretive to non-GAAP operating income in 2029. source
• Vertex will update 2026 guidance at the anticipated Q3:26 closing. source
• Given the expected close timing, Vertex expects a modest impact to 2026 revenue and non-GAAP operating expenses. source
• The presentation states Vertex’s 2023 goal of “5 launches in 5 years” was achieved early with the Crinetics acquisition. source

Impact estimates